Vaxcyte Inc. (PCVX) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Vaxcyte Inc. (PCVX)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

78.15

-3.02 (-3.72%)

At close: Jan 14, 2025, 3:59 PM

78.10

-0.06%

After-hours Jan 14, 2025, 05:01 PM EST

undefined% (undefined)

Bid	31.26
Market Cap	9.74B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-4.6
PE Ratio (ttm)	-16.99
Forward PE	n/a
Analyst	Buy

Ask	85
Volume	851,878
Avg. Volume (20D)	1,175,147
Open	81.46
Previous Close	81.17
Day's Range	77.53 - 81.46
52-Week Range	58.10 - 121.06
Beta	undefined

About PCVX

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a co...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jun 12, 2020

Employees 254

Stock Exchange NASDAQ

Ticker Symbol PCVX

Website https://vaxcyte.com

Analyst Forecast

According to 8 analyst ratings, the average rating for PCVX stock is "Buy." The 12-month stock price forecast is $140, which is an increase of 79.14% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

2 months ago · Source

-6.31%

Shares of vaccine stocks are trading lower After P... Unlock content with Pro Subscription

4 months ago · Source

+2.7%

Vaxcyte shares are trading higher after the company priced a $1.3 billion public offering.

News

4 months ago · seekingalpha.com

Vaxcyte's Broad-Spectrum Pneumococcal Vaccines Poised For Market Dominance By 2027

Vaxcyte's XpressCF platform enables the development of broad-spectrum vaccines, overcoming the limitations of traditional cell-based approaches. VAX-31 and VAX-24 are Vaxcyte's key value drivers. They...